Company intelligence / Profile preview
Ikaika Therapeutics
Oak Park, Illinois, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Ikaika Therapeutics is a preclinical-stage private biotech developing first-in-class anti-fibrotic monoclonal antibodies targeting latent transforming growth factor beta binding protein 4 (LTBP4). Their lead antibody (IKN-001/IKN mAb) stabilizes the LTBP4–TGF-β complex, reduces TGF-β activation, decreases fibrosis, and improves muscle function in preclinical muscular dystrophy models, including published improvements in diaphragm fibrosis and breathing in Duchenne muscular dystrophy mice.[2][3][4]
- Therapeutic areas
- CardiovascularNeurologyPulmonologyRare DiseasesMetabolic DisordersOncology
- Modalities
- Monoclonal antibodyAntibodyBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Northwestern University (Center for Genetic Medicine and scientific collaboration)[3][6]Adimab (antibody discovery and optimization partner)[3]NIH NINDS Blueprint Neurotherapeutics Network funding partnerships (UG3/UH3 program support)[3]
Beyond the preview
Go deeper on Ikaika Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ikaika Therapeutics.